Yazar "Ozcelik, Melike" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Comparison of the efficacy and safety of 3 months of CAPOX followed by 3 months of capecitabine and 6 months of CAPOX/FOLFOX in the adjuvant treatment of low-risk stage-III colon cancer treated surgically
    (Karger, 2023) Bardakci, Murat; Esmer, Derya; Hafizoglu, Emre; Yaslikaya, Sendag; Genc, Tugrul Burak; Ozcelik, Melike; Erdat, Efe Cem
    Introduction: In the adjuvant treatment of low-risk stage-III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since there are no data on this practice in the literature, we have no idea how often it is used. However, it should be noted that this application is used in some centers due to the cumulative neurotoxicity of oxaliplatin but there are insufficient data in the literature on its efficacy.Methods: The data of patients with colon cancer treated surgically who were followed up in 12 different oncology centers in Turkey between November 2004 and June 2022 were analyzed retrospectively.Results: The study included 194 patients. The treatment arms were as follows: 3 months of CAPOX followed by 3 months of capecitabine = arm A and CAPOX/FOLFOX (6 months) = arm B. There were 78 patients (40.2%) in arm A and 116 patients (59.8%) in arm B. The median age and sex distribution were similar between the treatment arms. The median follow-up period of all patients was 34.4 months (95% CI, 29.1-39.7). When arm A was compared with arm B, 3-year disease-free survival (DFS) was 75.3% vs. 88.4% and 5-year DFS was 75.3% vs. 82.8%, respectively. There were similar DFS outcomes between the treatment arms (p=0.09). Rates of any grade of neuropathy were numerically lower in arm A, but the difference between the treatment arms was not statistically significant (51.3% vs. 56.9%; p=0.44). The frequency of neutropenia was similar between the treatment arms.Discussion/Conclusion: In this study, the efficacy and safety of the 3 months of CAPOX followed by 3 months of capecitabine chemotherapy regimen in the adjuvant treatment of low-risk stage-III colon cancer treated surgically was proven. This result may also support the discontinuation of oxaliplatin at 3 months while continuing fluoropyrimidines, which is a common clinical practice but lacks sufficient data.
  • [ X ]
    Öğe
    Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study
    (Sage Publications Ltd, 2021) Koca, Sinan; Besiroglu, Mehmet; Ozcelik, Melike; Karaca, Mustafa; Bilici, Mehmet; Hacioglu, Bekir; Dogu, Gamze G.
    Purpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
  • [ X ]
    Öğe
    Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue.
    (Lippincott Williams & Wilkins, 2014) Demirci, Ayse; Alkis, Necati; Dane, Faysal; Yazilitas, Dogan; Durnali, Ayse; Inanc, Mevlude; Ozcelik, Melike
    [Abstract Not Available]